Trastuzumab Vedotin

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 05:36:18 GMT 2025` Edited by `admin` on `Wed Apr 02 05:36:18 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1\|TOXIN CONJUGATE
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	W95G28K44S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Trastuzumab Vedotin

Official Name

English

MRG-002

Preferred Name

English

Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated to auristatin E

Common Name

English

MRG 002 [WHO-DD]

Common Name

English

TRASTUZUMAB--VCMMAE CONJUGATE

Common Name

English

MRG002

Code

English

trastuzumab vedotin [INN]

Common Name

English

Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

898822

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

Code System Code Type Description

SMS_ID

300000050047

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

PRIMARY

INN

12531

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

PRIMARY

NCI_THESAURUS

C174205

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

PRIMARY

CAS

2740607-04-7

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

PRIMARY

FDA UNII

W95G28K44S

Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025

PRIMARY

From	To
4_134	4_194
4_23	4_88
3_134	3_194
3_23	3_88
2_370	2_428
2_264	2_324
2_223	4_214
2_147	2_203
2_22	2_96
1_370	1_428
1_264	1_324
1_232	2_232
1_229	2_229
1_223	3_214
1_147	1_203
1_22	1_96

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_300

Related Record Type Details


					Q3606FDE0B

VEDOTIN FRAGMENT

CONJUGATE COMPONENT->CONJUGATE

Amount:


					6603L01WUR

Cysteinyl vedotin

CONJUGATE COMPONENT->CONJUGATE

Amount:


					P188ANX8CK

CONJUGATE COMPONENT->CONJUGATE

Amount:


					7J9Y28299R

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2

TARGET->CONJUGATED TOXIN

Comments:

MRG002 potently inhibited proliferation of HER2 expressing cancer cells in vitro with IC50 ranged from 1.8±0.8 to 59.9±8.9 ng/mL,

Amount:

Related Record Type Details


					W95G28K44S

Trastuzumab Vedotin

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION		RESIDUE_SPECIFIC	Cysteine		Cysteinyl vedotin	6603L01WUR
AMINO ACID REMOVAL	[1_450] [2_450]	C-TERMINUS		Amount:	LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION				Amount:	PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL